| ANIA |
Accelerated National Innovation Adoption |
| BED |
binge eating disorder |
| BMI |
body mass index |
| BMS |
bariatric and metabolic surgery |
| CTAC |
community treatment and care |
| CVD |
cardiovascular disease |
| EQIA |
equality impact assessment |
| FPG |
fasting plasma glucose |
| GDM |
gestational diabetes mellitus |
| GIP |
glucose-dependent insulinotropic polypeptide |
| GLP-1 RA |
glucagon-like peptide-1 receptor agonist |
| GMC |
General Medical Council |
| GP |
general practitioner |
| HbA1c |
haemoglobin A1c/glycated haemoglobin |
| MAP |
Motivation, Action and Prompts |
| NES |
NHS Education for Scotland |
| NICE |
National Institute for Health and Care Excellence |
| OGTT |
oral glucose tolerance test |
| PCOS |
polycystic ovary syndrome |
| SHTG |
Scottish Health Technologies Group |
| SIGN |
Scottish Intercollegiate Guidelines Network |
| SIMD |
Scottish Index of Multiple Deprivation |
| SMC |
Scottish Medicines Consortium |
| SmPc |
Summary of Product Characteristics |
| UK |
United Kingdom |
Prevention and remission of type 2 diabetes (SIGN)
